| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Name | Posacona zole |
| CAS | 171228-49-2 |
| MF | C37H42F2N8O4 |
| MW | 700.777 |
| EINECS | 682-747-8 |
| Appearance | white Powder |
| Categories | API;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals |
| Fp | 9ºC |
| Storage temp. | -20°C Freezer |
Posaconazole is used for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as HSCT recipients with GVHD or those with hematologic malignancies with prolonged neutropenia from chemotherapy.
Posaconazole is also used for the treatment of oropharyngeal candidiasis (OPC), including OPC refractory to itraconazole and/or fluconazole therapy.
Posaconazole is also used to treat invasive infections by Candida, Mucor, and Aspergillus species in severely immunocompromised patients.
Posacona zole use to treat:
Invasive aspergillosis,Fusarium infection,Chromoblastomycosis and mycetoma,Coccidioidomycosis,Oropharyngeal candidosis
Prophylaxis of invasive fungal infections in patients at serious risk
With the exception of oropharyngeal candidosis and prophylaxis, use is presently restricted to patients with disease that is refractory to other antifungal drugs, or who are intolerant to them.
Posacona zole, launched in the UK, is the newest member of the a zole class of antifungal agents to reach the market. It is indicated for the treatment and prophylaxis of a range of invasive fungal infections, including aspergillosis,fusariosis, chromoblastomycosis, mycetoma, and coccidiomycosis in patients who are refractory to, or intolerant of, standard therapy with amphotericin B and/or itracona zole. In the US, it is approved for the prophylaxis of invasive Aspergillus and Candida infections in patients 13 years of age who are at high risk of developing these infections due to being severely immunocompromised. Additionally, it is approved for the treatment of oropharyngeal candidiasis. Posacona zole has an expanded spectrum of activity over other members of the a zole antifungals. In addition to potent activity against refractory cases of aspergillosis and flucona zole-resistant Candida, it demonstrates activity against Zygomycetes.
){kind=link}